What's this? This is an unbiased just-the-facts news summary about Ebola, Federal Food & Drug Administration, Kevin Whaley, LeafBio, Mapp, ZMapp, extracted from the original article by Newslines' contributors. To see the newsline of each topic, click the links below. Learn more

EbolaFederal Food & Drug AdministrationKevin WhaleyLeafBioMappZMappAnnouncement

Fast tracked

18 Sep, 2015

ZMapp is granted fast track approval in America. LeafBio says the grant is an “important milestone” which brings them closer to eventually gaining approval. The drug has been administered under emergency use authorization to nine infected patients in Africa in addition to two infected missionaries in Europe during its first clinical trial. LeafBio CEO Whaley:

We are gratified to receive this designation for ZMapp. We are hopeful that this step will accelerate its access once safety and efficacy are demonstrated to satisfaction by FDA in ongoing clinical trials.

View the full newsline: EbolaFederal Food & Drug AdministrationKevin WhaleyLeafBioMappZMapp

Add your comments below...